Investment Column: Ignore Wetherspoon's weather worries

Character Group; Oxford Biomedica


Our view: Hold

Share price: 463p (-0.7p)

Stories about pub closures seem to crop up every few weeks. JD Wetherspoon is an exception, continuing to open new outlets. That's a refreshing change, although not as refreshing as a cool pint of lager at one of its outlets on a warm day. Unfortunately for the company the weather has been cold, really cold, and as a result, people have stayed at home, relying on the supermarkets for their tipples even more than usual.

Which is a shame, because prior to the cold snap, Wetherspoon's was doing rather well, with sales on a rising trend. Just look at the numbers. For the first 10 weeks of the second quarter (to 3 January 2010), sales excluding those from new openings increased by 1.0 per cent, compared to 0.3 per cent growth in the first quarter (to 25 October 2009). Total sales for the same period increased by 5.3 per cent, compared to 4.5 per cent in the first quarter

However, for the quarter's full 12 weeks, sales decreased by 0.3 per cent excluding new openings. Total sales increased by 3.7 per cent.

But that should not detract from the overall investment case, which remains as strong as any in a sector which is struggling. The company's debt mountain of £435m remains a concern but talks over re-financing are "progressing well". It needs to be reduced (so no dividend) because the terms are likely to be tighter this time around thanks to the credit crunch. All the same, if you strip out the weather, the company is presenting an encouraging picture of its operations.

We've said before that Wetherspoon is the quality play in the sector and the shares deserve a premium. That said, at 12.8 times forecast 2010 full year earnings, they are hardly cheap. Last time we looked at the company (in May) we said hold at 447.25p and they've risen slightly since then. The shares are too pricey to recommend buying more, but the company is doing well, so stick with it. Hold.

Character Group

Our view: Buy

Share price: 78p (+3.5p)

According to the much-loved theme tune, Postman Pat thinks he's a very lucky man. Shareholders in Character Group, which owns the rights to make toys of the Greendale postie and his sidekick Jess, may not feel quite so felicitous.

Character designs, develops and distributes toys, games and gifts to 30 countries around the world. Also on its roster are Fireman Sam, Scooby Doo and, um, the Terminator. In its recent history the AIM-listed stock has suffered a few bumps, falling from above 200p in October 2007 to as low as 23p early last year as the collapse of Woolworths shook the business.

The group put out a positive update yesterday, shaking off an 8.5 per cent fall in the toy market in 2009, as it posted a 1.2 per cent boost in the first four months of its financial year. After giving its products a facelift, management expects a significant turnaround in pre-tax profits in the first half of 2010.

The optimism drove analysts at Charles Stanley to upgrade full year estimates from £2m to £3.5m yesterday. With a price to earnings ratio of 6.6 times 2012 earnings per share, this looks awfully cheap, although much depends on the success of new products such as the latest Doctor Who range. Certainly, the Terminator full head mask and voice changer is a winner (and great fun for terrifying friends and family), and this year the shares – to paraphrase the original Arnold Schwarzenegger movie – might well be back. Buy.

Oxford Biomedica

Our view: Buy

Share price: 12p (+0.25p)

There was a time, not too long ago, when analysts used to say that Oxford Biomedica was like an onion: peel away the various layers, and ultimately you're left with little.

But things are changing for the AIM-listed gene therapy group. Yesterday it announced that UshStat, a treatment for Usher Syndrome, a rare but nonetheless nasty genetic disorder that leads to deafness and blindness, has been granted so-called orphan status by the European regulators. The move grants the company 10 years of marketing exclusivity, and reduces regulatory fees in the future.

Small biotech companies depend on a strong flow of news to get investors excited, especially as they are likely to be asked for more money in the future to fund research, while the notion of a dividend is laughable.

UshStat is the second of its treatments to be granted orphan status in the last six weeks after Stargen, a potential drug for treating Stargardt's disease, was similarly approved. The share price has responded in kind, putting on nearly 50 per cent in the last 12 months alone. Investors should not get carried away. Biotech is, and always will be, one of the most high risk sectors, but you could do worse than to back Oxford Biomedica. Buy.

Start your day with The Independent, sign up for daily news emails
Arts and Entertainment
Joe Cocker performing on the Stravinski hall stage during the Montreux Jazz Festival, in Montreux, Switzerland in 2002
musicHe 'turned my song into an anthem', says former Beatle
News
Clarke Carlisle
sport
Sport
footballStoke City vs Chelsea match report
Arts and Entertainment
theatreThe US stars who've taken to UK panto, from Hasselhoff to Hall
PROMOTED VIDEO
ebooks
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Life and Style
Approaching sale shopping in a smart way means that you’ll get the most out of your money
life + styleSales shopping tips and tricks from the experts
News
newsIt was due to be auctioned off for charity
News
Coca-Cola has become one of the largest companies in the world to push staff towards switching off their voicemails, in a move intended to streamline operations and boost productivity
peopleCoca-Cola staff urged to switch it off to boost productivity
Environment
Sir David Attenborough
environment... as well as a plant and a spider
Voices
'That's the legal bit done. Now on to the ceremony!'
voicesThe fight for marriage equality isn't over yet, says Siobhan Fenton
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

The Jenrick Group: Night Shift Operations Manager

£43500 per annum + pension + holidays: The Jenrick Group: Night Shift Operatio...

SThree: Trainee Recruitment Consultant - LONDON

£20000 - £25000 per annum + OTE £40,000 + Car + Pension: SThree: SThree are a ...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £35K: SThree: We consistently strive to be the...

SThree: Graduate Recruitment Consultant

£20000 - £25000 per annum + OTE £35000: SThree: SThree are a global FTSE 250 b...

Day In a Page

Isis in Iraq: Yazidi girls killing themselves to escape rape and imprisonment by militants

'Jilan killed herself in the bathroom. She cut her wrists and hanged herself'

Yazidi girls killing themselves to escape rape and imprisonment
Ed Balls interview: 'If I think about the deficit when I'm playing the piano, it all goes wrong'

Ed Balls interview

'If I think about the deficit when I'm playing the piano, it all goes wrong'
He's behind you, dude!

US stars in UK panto

From David Hasselhoff to Jerry Hall
Grace Dent's Christmas Quiz: What are you – a festive curmudgeon or top of the tree?

Grace Dent's Christmas Quiz

What are you – a festive curmudgeon or top of the tree?
Nasa planning to build cloud cities in airships above Venus

Nasa planning to build cloud cities in airships above Venus

Planet’s surface is inhospitable to humans but 30 miles above it is almost perfect
Surrounded by high-rise flats is a little house filled with Lebanon’s history - clocks, rifles, frogmen’s uniforms and colonial helmets

Clocks, rifles, swords, frogmen’s uniforms

Surrounded by high-rise flats is a little house filled with Lebanon’s history
Return to Gaza: Four months on, the wounds left by Israel's bombardment have not yet healed

Four months after the bombardment, Gaza’s wounds are yet to heal

Kim Sengupta is reunited with a man whose plight mirrors the suffering of the Palestinian people
Gastric surgery: Is it really the answer to the UK's obesity epidemic?

Is gastric surgery really the answer to the UK's obesity epidemic?

Critics argue that it’s crazy to operate on healthy people just to stop them eating
Homeless Veterans appeal: Christmas charity auction Part 2 - now LIVE

Homeless Veterans appeal: Christmas charity auction

Bid on original art, or trips of a lifetime to Africa or the 'Corrie' set, and help Homeless Veterans
Pantomime rings the changes to welcome autistic theatre-goers

Autism-friendly theatre

Pantomime leads the pack in quest to welcome all
The week Hollywood got scared and had to grow up a bit

The week Hollywood got scared and had to grow up a bit

Sony suffered a chorus of disapproval after it withdrew 'The Interview', but it's not too late for it to take a stand, says Joan Smith
From Widow Twankey to Mother Goose, how do the men who play panto dames get themselves ready for the performance of a lifetime?

Panto dames: before and after

From Widow Twankey to Mother Goose, how do the men who play panto dames get themselves ready for the performance of a lifetime?
Thirties murder mystery novel is surprise runaway Christmas hit

Thirties murder mystery novel is surprise runaway Christmas hit

Booksellers say readers are turning away from dark modern thrillers and back to the golden age of crime writing
Anne-Marie Huby: 'Charities deserve the best,' says founder of JustGiving

Anne-Marie Huby: 'Charities deserve the best'

Ten million of us have used the JustGiving website to donate to good causes. Its co-founder says that being dynamic is as important as being kind
The botanist who hunts for giant trees at Kew Gardens

The man who hunts giants

A Kew Gardens botanist has found 25 new large tree species - and he's sure there are more out there